« Back
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
09/07/23 9:00 AM EDT
– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne
“On behalf of Sarepta and the selection committee, we are proud to announce the recipients of
2023-2024 Route 79 Scholarship Recipients
- John "Jack" Becker,
Embry-Riddle Aeronautical University ,Daytona Beach Christopher Cameron ,Ball State University Jacob Colby , TheEvergreen State College Kyle Cox ,Texas A&M University - Agranil Das,
Stony Brook University Blake Deakin ,Arizona State University Corbin Fanning ,Texas A&M University Aiden Fecteau ,Eastern Connecticut State University Yuvaraj Gambhir ,University of Pennsylvania Declan Hickey ,Curry College Yujia Ji ,The Ohio State University Elliott Johnson ,Lebanon Valley College Ryan Lugo ,State University of New York at New Paltz Brian Madura ,New Jersey Institute of Technology Josh Pflueger ,Texas Christian University Jasdeep Singh ,Cleveland Institute of Art Vedant Singhania ,San Jose State University Connor Underwood ,Pikes Peak State College Braden Van Eperen ,Union College Jack Wolf ,University of Akron
2023-2024 Route 79 Sibling Scholarship Recipients
Hailey Baquiran ,Dominican University of California Ellyn Beebe ,University of Tennessee atMartin Isabel Dreher ,University of New Hampshire Lance Hains ,West Chester University - Grace Lee,
University of Colorado Boulder
About
About
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230907578056/en/
Investor:
iestepan@sarepta.com
Media:
tsorrentino@sarepta.com
sismith@sarepta.com
Source:
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.